13F Holdings
中文EN

AGIO AGIOS PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1439222 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY214.4%
TTM net income YoY7.1%
TTM EPS YoY10.0%
Revenue 3-yr CAGR80.3%
Net income 3-yr CAGR—

Margins

Gross margin93.8%
Operating margin-297.7%
Net margin-264.8%
FCF margin-238.5%
EBITDA margin—

Returns

ROE-32.9%
ROA-30.4%
ROIC (approx.)-32.4%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets8.0%
Debt / equity0.00x
Current ratio9.69x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue3.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$54.03M$36.50M$26.82M$14.24M$0
Cost of revenue$6.34M$4.17M$2.88M$1.70M$0
Gross profit$47.68M$32.33M$23.94M$12.54M$0
R&D expense$339.54M$301.29M$295.53M$279.91M$256.97M
SG&A expense$180.28M$156.78M$119.90M$121.67M$121.44M
Operating income-$472.13M-$425.74M-$391.49M-$389.05M-$378.42M
Pretax income-$413.80M$717.97M-$352.09M-$231.80M-$356.51M
Income tax-$1.02M$44.24M$0$0—
Net income-$412.78M$673.73M-$352.09M-$231.80M$1.60B
EBITDA-$466.93M-$420.04M-$384.89M-$380.65M-$369.62M
EPS (basic)-7.1211.86-6.33-4.2326.55
EPS (diluted)-7.1211.64-6.33-4.2326.55
Weighted avg. shares (diluted)57.97M57.89M55.65M54.79M60.45M
Balance sheet
Cash & equivalents$89.13M$76.25M$88.20M$139.26M$203.13M
Short-term investments$765.29M$817.46M$688.72M$643.86M$816.89M
Inventory$32.92M$27.62M$19.08M$8.49M$0
Current assets$942.05M$965.60M$833.84M$832.77M$1.06B
PP&E, net$10.78M$11.68M$15.38M$22.99M$28.92M
Total assets$1.30B$1.66B$937.12M$1.24B$1.44B
Current liabilities$82.21M$81.16M$67.95M$62.63M$59.83M
Total liabilities$104.11M$122.24M$126.10M$137.90M$145.76M
Shareholders' equity$1.19B$1.54B$811.02M$1.10B$1.29B
Shares outstanding58.45M57.16M55.95M55.04M54.33M
Cash flow statement
Operating cash flow-$372.98M-$389.84M-$296.06M-$309.48M-$407.32M
Capital expenditure$4.32M$1.69M$999,000$4.88M$5.74M
Free cash flow-$377.29M-$391.53M-$297.06M-$314.36M-$413.06M
Investing cash flow$377.18M$363.44M$239.57M$243.26M$1.25B
Financing cash flow$8.68M$14.44M$5.43M$2.35M-$765.77M
Depreciation & amortization$5.20M$5.70M$6.60M$8.40M$8.80M
Stock-based compensation$52.55M$42.85M$44.77M$49.30M$53.51M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.